Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 19130-nm albumin-bound paclitaxel 16Specimen Handling 15Irinotecan 11Magnetic Resonance Spectroscopy 10Fluorouracil 10Leucovorin 9Biopsy 9Oxaliplatin 8pembrolizumab 7Cyclophosphamide 7fludarabine 6Cisplatin 5Pemetrexed 4Cetuximab 4Albumin-Bound Paclitaxel 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3durvalumab 3dehydroftorafur 3aldesleukin 3Taxes 3Radiosurgery 3Nivolumab 3Immunoglobulin G 3Disulfides 3Carboplatin 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × KP 1339 × 30 days × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡